Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe : a Central European Cooperative Oncology Group analysis
Authors:ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Author)
ID Ciuleanu, Tudor (Author)
ID Berzinec, Peter (Author)
ID Galffy, Gabriela (Author)
ID Jakopović, Marko (Author)
ID Jassem, Jacek (Author)
ID Jovanovic, Dragana (Author)
ID MIhaylova, Zhasmina (Author)
ID Ostoros, Gyula (Author)
ID Thallinger, Christiane (Author)
ID Zemanova, Milada (Author)
ID Zielinski, Christoph (Author)
Files:.pdf PDF - Presentation file, download (341,24 KB)
MD5: B9055D61D512AA3EFA4A3D6D02005C75
URL URL - Source URL, visit
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Background. Treatment of non-small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune-oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel drugs for NSCLC are poorly accessible in Central and Eastern European (CEE) countries. Material and Methods. The Central European Cooperative Oncology Group conducted a survey among experts from 10 CEE countries to provide an overview on the availability of novel drugs for NSCLC and time from registration to reimbursement decision in their countries. Results. Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors were reimbursed and available in all countries, for other registered therapies - even for ALK inhibitors and checkpoint inhibitors in first-line - there were apparent gaps in availability and/or reimbursement. There was a trend for better availability of drugs with longer time from EMA marketing authorization. Substantial differences in access to novel drugs among CEE countries were observed. In general, the availability of drugs is not in accordance with the Magnitude of Clinical Benefit Scale (MCBS), as defined by the European Society for Medical Oncology (ESMO). Time spans between drug registrations and national decisions on reimbursement vary greatly, from less than 3 months in one country to more than 1 year in the majority of countries. Conclusion. The access to novel drugs for NSCLC in CEE countries is suboptimal. To enable access to the most effective compounds within the shortest possible time, reimbursement decisions should be faster and ESMO MCBS should be incorporated into decision making.
Keywords:non-small cell lung cancer, treatment, novel drugs, Central Europe, Southeastern Europe
Publication status:Published
Publication version:Version of Record
Place of publishing:ZDA
Publisher:Wiley Periodicals, Inc. on behalf of AlphaMed Press
Year of publishing:2020
Number of pages:str. e598-e601
Numbering:Vol. 25, iss. 3
PID:20.500.12556/DiRROS-12196 New window
ISSN on article:1549-490X
DOI:10.1634/theoncologist.2019-0523 New window
COBISS.SI-ID:2048592241 New window
Copyright:© 2019 The Authors
Note:Nasl. z nasl. zaslona; Opis vira z dne 6. 12. 2019;
Publication date in DiRROS:24.07.2020
Copy citation
Share:Bookmark and Share

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:The oncologist
Shortened title:Oncologist
Publisher:AlphaMed Press
COBISS.SI-ID:521539609 New window


License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:24.07.2020

Secondary language

Keywords:nedrobnocelični rak pljuč, zdravljenje, nova zdravila, Srednja Evropa, Jugovzhodna Evropa